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Members of the low-density lipoprotein (LDL) receptor gene family have a diverse set of biological functions
that transcend lipid metabolism. Lipoprotein receptors have broad effects in both the developing and
adult brain and participate in synapse development, cargo trafficking, and signal transduction. In addition,
several family members play key roles in Alzheimer’s disease (AD) pathogenesis and neurodegeneration.
This Review summarizes our current understanding of the role lipoprotein receptors play in CNS function
and AD pathology, with a special emphasis on amyloid-independent roles in endocytosis and synaptic
dysfunction.Introduction
The low-density lipoprotein receptor (LDLR) family is a highly
conserved receptor family with diverse functions in cellular phys-
iology. The core members of the LDL receptor family include the
LDL receptor (Yamamoto et al., 1984), LDLR-related protein 1
(LRP1) (Herz et al., 1988), the very-low-density lipoprotein recep-
tor (VLDLR) (Takahashi et al., 1992), megalin (LRP2) (Saito et al.,
1994), Apoer2 (LRP8) (Kim et al., 1996; Novak et al., 1996), LRP4
(Nakayama et al., 1998), and LRP1b (Liu et al., 2000). Orthologs
of LDLR family members have been found in species throughout
the animal kingdom, highlighting the fundamental role these re-
ceptors play in basic cellular processes.
The members of the LDLR family share a conserved structure.
At the C terminus, a short cytoplasmic tail contains one to three
NPxY motifs, which facilitate signal transduction and endocytic
trafficking through interactions with cytosolic adaptor proteins
(Gotthardt et al., 2000). The extracellular domain has a varying
number of complement-type repeats and epidermal growth fac-
tor precursor homology domains, which are required for ligand
binding and pH-dependent ligand release, respectively (Davis
et al., 1987; Esser et al., 1988). Additionally, the extracellular
domain can interact with a variety of coreceptors.
The lipoprotein receptors bind a wide variety of ligands with
differing specificity, helping to explain the diversity of their
actions. These ligands include, but are not limited to, develop-
mental proteins (Sonic hedgehog [Christ et al., 2012],Wnt [Tamai
et al., 2000], and Reelin [D’Arcangelo et al., 1999]), apolipopro-
teins (ApoE and ApoB), proteases and protease inhibitors (a2-
macroglobin [Strickland et al., 1990]), carriers of plasma vitamins
(Moestrup and Verroust, 2001), chaperones (RAP [Kounnas
et al., 1992]), and inflammatory mediators (TGFb [Muratoglu
et al., 2011]).
Through interactions with these ligands, the lipoprotein recep-
tors have a diverse set of functions in the developing and adult
nervous system, from lipoprotein trafficking, to synaptic plas-ticity, to cell migration and development. Additionally, lipoprotein
receptors affect neurodegenerative processes and are the key
receptors for the main Alzheimer’s disease (AD) risk factor,
ApoE4. This Review will touch on each of these aspects of lipo-
protein receptor signaling in the nervous system.
The Lipoprotein Receptors and Cholesterol Metabolism
The lipoprotein receptors were initially identified for their role
in peripheral cholesterol transport. Cholesterol is required for
several processes in the body. It is a key component of the
plasma membrane and a precursor for the production of steroid
hormones. In the periphery, lipoprotein receptors bind triglycer-
ide- and cholesterol-carrying lipoprotein particles such as chylo-
microns, VLDL, and LDL for endocytosis via clathrin-coated pits
into cells for further metabolism (Go and Mani, 2012). Similar to
their role in the periphery, lipoprotein receptors mediate choles-
terol transport in theCNS.Mostplasma lipoproteins cannot cross
the blood-brain barrier, and thus cholesterol-carrying particles
are generally produced within the CNS (Bjo¨rkhem et al., 1998).
In the CNS, glia-derived cholesterol is essential for the formation
andmaintenance ofmature synapses (Mauch et al., 2001). Astro-
cytes release ApoE-containing ‘‘HDL-like’’ particles to transport
cholesterol and phospholipids between glia and neurons (Boyles
et al., 1985; Pitas et al., 1987). ApoE binds to a variety of cell sur-
face receptors in the LDLR family for particle uptake, including
LDLR, LRP1, VLDLR, and Apoer2 (Beffert et al., 2004). Lrp1
appears to have the highest transport capacity for ApoE, due to
its rapid endoyctic recycling rates (Li et al., 2001). Moreover, se-
lective deletion of Lrp1 in forebrain neurons leads to a global
defect in brain lipid metabolism and neurodegeneration in mice
(Liu et al., 2010). Other lipoprotein receptor family members
may also participate in CNS cholesterol homeostasis.
The importance of cholesterol homeostasis for brain function
is highlighted by Niemann-Pick type C (NPC) disease. In NPC,
autosomal recessive mutations in NPC1 or NPC2 result inNeuron 83, August 20, 2014 ª2014 Elsevier Inc. 771
Figure 1. ApoE, Reelin, and Synaptic
Plasticity
(A) Reelin binds to its receptor, Apoer2, activating
a signaling cascade through Dab1 and SFKs
to phosphorylate NMDA receptors, resulting in
greater Ca2+ influx upon glutamate signaling
(Benhayon et al., 2003; Chen et al., 2005). Dab1
also acts to counteract Ab and PP2B’s effects on
Akt, GSK3b, and tau phosphorylation (Beffert et al.,
2002; Durakoglugil et al., 2009).
(B) Reelin signaling results in the endocytosis of
Apoer2, AMPA receptors, and NMDA receptors.
ApoE isoforms differentially affect the recycling of
these endosomes (Chen et al., 2010). ApoE3-con-
taining endosomes readily recycle back to the
surface, while those containing ApoE4 remain
trapped (trapped vesicles are displayed at reduced
size).
(C) Apoer2 and EphB2 bind the NR2 and NR1
subunits of NMDAR, respectively, regulating re-
ceptor function and endocytosis (Beffert et al., 2005; Dalva et al., 2000). Reelin binds to EphB2 and Apoer2 through independent, distinct sites (Bouche´ et al.,
2013). Akt, protein kinase B; AMPA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid; ApoE, apolipoprotein E; Apoer2, apolipoprotein E receptor 2;
Dab1, disabled-1; glu, glutamate; GSK3b, glycogen synthase kinase 3 beta; LTP, long-term potentiation; NMDA, N-methyl-D-aspartate; PI3K, phosphoinositide
3-kinase; PP2B, protein phosphatase 2B, calcineurin; SFKs, Src-family kinases.
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cholesterol and lipids in the lysosome and a deficiency of these
molecules for use both in the membrane and as a precursor for
steroid synthesis (Carstea et al., 1997; Naureckiene et al.,
2000). NPC is characterized primarily by progressive neurode-
generation, which indicates the brain’s high requirement for
cholesterol relative to other organs.
Lipoprotein Receptors and the Developing Brain
Several lipoprotein receptors play a vital role in the developing
embryo. Megalin, or Lrp2, is a 600 kDa lipoprotein receptor
expressed predominantly in the developing embryo and the
mammalian kidney (Saito et al., 1994). Lrp2 is required for normal
organogenesis, and Lrp2 knockout mice have holoprosence-
phaly with fused hemispheres and no olfactory bulbs (Willnow
et al., 1996). This phenotype results from increased BMP4
expression and a reduction of sonic hedgehog (Shh) expression,
which leads to a loss of interneurons and oligodendroglial cell
populations (Spoelgen et al., 2005). Individuals with autosomal
recessive loss-of-function mutations in LRP2 develop Donnai-
Barrow syndrome, which is characterized by facial dysmorphol-
ogy, ocular and hearing anomalies, and agenesis of the corpus
callosum (Kantarci et al., 2007).
The lipoprotein receptors Apoer2 and Vldlr also affect develop-
ment as mediators of Reelin signaling. Reelin is a large secreted
extracellular matrix protein, released early in development by
Cajal-Retzius cells and later in life by a subset of GABAergic inter-
neurons (Curran and D’Arcangelo, 1998). Reelin signaling is
required forproperneuronalmigrationandmaturation, andReelin
knockout (reeler) mice have inverted cortical layering, cerebellar
hypoplasia, and immature synapses (Falconer, 1951; Niu et al.,
2008).Reelermice also have impaired learning andmotor coordi-
nation as well as severe neurodevelopmental deficits that lead to
strain background-dependent lethality by about 5 weeks of age
(D’Arcangelo et al., 1995). Since Reelin uses both Apoer2 and
Vldlr to mediate its signaling, Apoer2 and Vldlr double knockout
mice also have a reeler phenotype (Trommsdorff et al., 1999).
Patients with mutations in RELN or VLDLR have been identified772 Neuron 83, August 20, 2014 ª2014 Elsevier Inc.that recapitulate certain aspects of the reeler phenotype (Hong
et al., 2000; Ozcelik et al., 2008), which underscores the impor-
tance of these receptors in the development of the CNS.
Lipoprotein Receptors, Reelin, and Synaptic Plasticity
Several of the lipoprotein receptors are expressed in the adult
CNS. Lrp1 is expressed in astrocytes, microglia, and neurons
in the postsynaptic density (May et al., 2004). VLDLR is ex-
pressed by many cell types, and in the brain it is found in glia,
neuroblasts, matrix cells, and pyramidal neurons on cell mem-
branes outside of lipid rafts (Christie et al., 1996; Duit et al.,
2010). Similarly, LDLR is expressed in both astrocytes and neu-
rons (Fan et al., 2001). Conversely, Apoer2 is largely restricted to
the testes and brain, where it is expressed in neurons throughout
the CNS and traffics into the postsynaptic density (Beffert et al.,
2005; Clatworthy et al., 1999). Due to their localization and
expression in neurons, lipoprotein receptors are well-placed to
affect synaptic function and synaptic plasticity.
The lipoprotein receptors Apoer2 and Vldlr play a role in synap-
tic plasticity through their interactionwith the glycoprotein Reelin.
At the adult synapse, Reelin has a key effect of enhancing long-
term potentiation (LTP). Reelin binding clusters Apoer2 and Vldlr,
leading to receptor dimerization and tyrosine phosphorylation of
the cytosolic protein Dab1 (Benhayon et al., 2003; D’Arcangelo
et al., 1999; Herz and Chen, 2006; Hiesberger et al., 1999; Howell
et al., 1997;Strasser et al., 2004).Dab1 thenactivatesSrc tyrosine
kinases (SFKs), including Fyn, which phosphorylate NMDA re-
ceptors, enhancing their Ca2+ influx (Chen et al., 2005). This
increased Ca2+ influx allows for a stronger NMDA current at
similar levels of glutamate release, resulting in greater AMPA re-
ceptor insertion into the membrane and enhanced LTP (Weeber
et al., 2002; Figure 1A). Consistent with its ability to enhance
LTP, acute intraventricular Reelin injections improvememoryper-
formance of wild-typemice and can rescue learning andmemory
deficits in heterozygous reelermice (Rogers et al., 2011, 2013).
The robust effect of Reelin signaling has led to a search for
other Reelin receptors. In addition to Apoer2 and Vldlr, Reelin
also binds EphB2, a member of the EphB receptor family
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CNS development and synaptic function (Klein, 2009; Xu and
Henkemeyer, 2012). EphB2 activation by its ligand Ephrin-B1 re-
sults in the clustering of EphB2 and NMDA receptors and pro-
motes excitatory synaptic development (Dalva et al., 2000). In
mature synapses, EphB2 promotes synaptic targeting of NR2B
subunits, which allows greater calcium influx upon NMDAR acti-
vation and may shift the synaptic plasticity balance toward LTP
(Nolt et al., 2011). In vitro, Reelin can at least partially activate
EphB2 signaling; however, the effects of Reelin-mediated
EphB2 signaling on NMDA receptor targeting and adult synaptic
function have yet to be determined (Bouche´ et al., 2013). Intrigu-
ingly, Apoer2 binds NR2 to promote its phosphorylation, while
EphB2 binds NR1 (Beffert et al., 2005; Dalva et al., 2000; Hoe
et al., 2006). Reelin binds to each of these receptors at a distinct
and separate site, suggesting that Apoer2, NMDAR, and EphB2
may form a macromolecular complex at the synapse (Bouche´
et al., 2013) (Figure 1C). In addition to EphB receptors, it has
been reported that LDLR may interact with Reelin (D’Arcangelo
et al., 1999), albeit much more weakly than Apoer2 and Vldlr.
Functionally, these are the main Reelin receptors, since
Apoer2/Vldlr double knockout mice are phenotypically identical
to reeler mice (Trommsdorff et al., 1999).
Most studies of the synaptic role of Reelin have focused on its
postsynaptic effects; however, new research suggests that
Reelin also affects the release of VAMP7-containing synaptic
vesicles (Bal et al., 2013). Previously, Apoer2 and Vldlr had
been thought to be predominantly postsynaptic proteins. Intrigu-
ingly, reeler mice have more vesicles at the presynaptic bouton
and a reduction in SNAP25, an element of the vesicle fusion
machinery, suggesting impairment in vesicle fusion and release.
However, this effect is not dependent on either Apoer2 or Vldlr
but rather the integrin pathway (Hellwig et al., 2011). The precise
details by which Reelin signals at the presynapse and the role of
Reelin receptor signaling remain to be clarified.
The Role of Lipoprotein Receptors in the Peripheral
Nervous System
The neural function of lipoprotein receptors is not limited to the
brain; in fact, they play a large role in the development of the
neuromuscular junction (NMJ). The vertebrate NMJ is a special-
ized cholinergic synapse in which presynaptic motor neurons
connect with postsynaptic muscle fibers at the motor endplate.
The lipoprotein receptor Lrp4 plays several roles in NMJ forma-
tion. First, Lrp4 forms a complex with MuSK to prepattern the
muscle (Kim and Burden, 2008). Activation of MuSK results in
the recruitment of several downstream pathways that result in
nicotinic acetylcholine receptor (AChR) clustering. When the
motor neuron arrives, it releases agrin, which stimulates MuSK
to promote maturation of the synapse. Lrp4 is required for the
relay of the agrin signaling to MuSK and in the absence of
Lrp4, agrin’s ability to induce MuSK phosphorylation is minimal
(Kim et al., 2008; Zhang et al., 2008). Finally, independent of agrin
or MuSK, Lrp4 acts as a retrograde messenger to promote pre-
synaptic vesicle clustering (Yumoto et al., 2012). Surprisingly,
Lrp4 only seems to be required for NMJ development in some
mammalian species. While Lrp4 knockout mice exhibit neonatal
lethality due to failure to form the NMJ (Weatherbee et al., 2006),homozygous mutations in LRP4 that would be predicted to
abolish its functionality cause Cenani-Lenz syndrome in humans
andmulefoot disease in cattle (Johnson et al., 2006; Karner et al.,
2010; Li et al., 2010), with apparently functional NMJs. These
findings could point to a different mechanism in the organization
of the NMJ in cattle and humans or a redundancy that may
compensate for functional Lrp4 loss. This redundancy could
potentially be mediated by Lrp10, an LDLR family member that
is virtually identical to Lrp4; however, it remains to be determined
whether LRP10 indeed arose from a recent gene duplication.
The amyloid precursor protein, APP, which is discussed in
depth later in the next section for its role in Alzheimer’s disease,
also takes part in NMJ development. APP, or its paralogue
APLP2, is required both pre- and postsynaptically for NMJ
development (Akaaboune et al., 2000; Wang et al., 2005). One
hypothesis is that APP acts transsynaptically to promote cross-
talk between the pre- and postsynaptic compartments. While
this has not been conclusively shown, it is known that APP can
bind both to itself and to APLP2 in trans to promote cell adhesion
in vitro (Soba et al., 2005). At the presynaptic side, APP interac-
tions promote choline transporter (CHT) activity and expression,
and they promote L-type calcium channel function, both of
which are required for proper NMJ function (Wang et al., 2007;
Yang et al., 2007). Finally, APP acts postsynaptically on the
motor endplate to promote Lrp4 and MuSK interaction (Choi
et al., 2013). These findings at peripheral synapses may also
apply at central synapses and point the way for future
studies on the role of lipoprotein receptors in central synapse
development.
Lipoprotein Receptors and Neurodegenerative Disease
Alzheimer’s disease (AD) is a devastating neurodegenerative dis-
order characterized by progressivememory loss and a patholog-
ical accumulation of amyloid plaques and neurofibrillary tangles.
Considerable research into the disease has focused on the ge-
netic, cognitive, and pathological changes found in individuals
with early-onset familial disease, who represent approximately
1% of the patient population. These individuals have mutations
in either the amyloid precursor protein (APP) or its cleavage pro-
teins PS1 and PS2, resulting in the early accumulation of plaque-
forming amyloid b (Ab) (Weggen and Beher, 2012). However, the
majority of AD patients have late-onset disease (LOAD), with no
mutations in the Ab-generating machinery. The major genetic
risk factor for LOAD is the ε4 isoform of apolipoprotein E—a
cholesterol transport protein.
In humans, ApoE exists in three isoforms that differ at two res-
idues: ε2 (ApoE2 with cys112 and cys158), ε3 (ApoE3 with
cys112 and arg158), and ε4 (ApoE4 with arg112 and arg158).
These variations confer significant differences in disease risk.
ApoE3 is the most common isoform and thus is considered the
gold standard from the population genetic risk perspective.
Relative to ApoE3, ApoE4 is present in approximately 15%–
20% of the population and is associated with greatly increased
risk and earlier onset of AD (Corder et al., 1993; Schmechel
et al., 1993). Meanwhile, the ApoE2 isoform is protective against
AD relative to ApoE3 and ApoE4 (Corder et al., 1994). The struc-
tural differences between these isoforms contribute to differ-
ences in protein conformation, receptor binding, and endocyticNeuron 83, August 20, 2014 ª2014 Elsevier Inc. 773
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netic association studies of polymorphisms in lipoprotein recep-
tors with AD risk have only revealed potential minor effects of
LRP1 (Beffert et al., 1999; Jin et al., 2013). This may be due to
the fact that several of the lipoprotein receptors have key devel-
opmental roles, which could preclude major effects on neurode-
generation. By contrast, a significant association of SORL1 with
AD has been reported (Rogaeva et al., 2007), which has been
corroborated mechanistically on the molecular level (Schmidt
et al., 2012).
What links lipoprotein receptors to AD? The difficulty in finding
the answer stems from the fact that late-onset AD is a multi-
factorial disease involving endocytic dysfunction, lipoprotein
signaling, and synaptic dysregulation—essentially three different
disciplines. The remainder of this Review focuses on the variety
of roles played by lipoprotein receptors in neurodegenerative
processes.
APP Processing and the Endosome
The pathological hallmark of Alzheimer’s disease is progressive
accumulation of amyloid plaques. These plaques are formed of
aggregated amyloid b (Ab), the end product of sequential cleav-
age of amyloid precursor protein (APP) (reviewed in Zhang et al.,
2012). Briefly, APP is cleaved first by b-secretase (BACE-1) to
sAPPb and b C-terminal fragment (bCTF) (Cai et al., 2001).
bCTF is then cleaved by g-secretase: a complex of multiple pro-
teins that includes presenilin 1 or 2 (PS1 or PS2), APH, nicastrin,
and PEN2 (St George-Hyslop and Fraser, 2012), resulting in the
final cleavage product, Ab.
The APP metabolites resulting from this sequential cleavage
play their own roles in neuronal function, reviewed in depth in
(Chow et al., 2010). sAPPb, generated by b-cleavage, appears
to be involved in synaptic pruning and apoptosis (Nikolaev
et al., 2009). In contrast to amyloidogenic b-cleavage, APP can
be cleaved by a-secretase within the Ab segment to generate
the nonamyloidogenic sAPPa (Vingtdeux and Marambaud,
2012). sAPPa is generally considered to be neuroprotective,
enhancing LTP and spatial learning (Taylor et al., 2008). The
other cleavage products created by a- and b-cleavage, CTF83
and CTF99, respectively, do not have well-defined roles. How-
ever, g-secretase cleavage of the CTFs results in the release of
the APP Intracellular Domain (AICD), which binds Fe65 and
TIP60 for potential transcriptional activation of downstream tar-
gets (Cao and Su¨dhof, 2001), ultimately promoting cell death and
impairing neurogenesis (Ghosal et al., 2010; Wang et al., 2014).
The final and most-studied products of APP cleavage are the
Ab species, predominantly Ab40 and some Ab42. Of these two
species, Ab42 is considered to be more amyloidogenic and
thus more toxic (Aoki et al., 2008; Kim et al., 2007; McGowan
et al., 2005). Mutations causing early-onset Alzheimer’s disease
directly affect this process—mutations in APP facilitate cleavage
by BACE1 to amyloidogenic species, while mutations in PSEN1
and PSEN2 enhance their g-cleavage ability and tend to produce
a higher Ab42:Ab40 ratio (Weggen and Beher, 2012). By contrast,
in LOAD, there is no inherent dysfunction of the key enzymes of
Ab generation, yet Ab still accumulates.
Whether APP isaor b-cleaved is determinedby the localization
of APP processing proteins. a-secretase is active at the mem-774 Neuron 83, August 20, 2014 ª2014 Elsevier Inc.brane surface, whereas BACE1 is most active at the lower pH
found in endosomes (Cole and Vassar, 2007). As a result, condi-
tions that result in increased trafficking of APP to the endosome
are pro-amyloidogenic, whereas those that maintain APP at
the surface are anti-amyloidogenic. Moreover, in healthy brains,
APP and BACE1 are largely localized to different compartments,
while ADbrains show increased colocalization of the twoproteins
within acidic microdomains (Das et al., 2013). Additionally, over-
expression of ApoE4 promotes colocalization of APP andBACE1
in vitro (Rhinn et al., 2013). However, localization to the mem-
brane surface is not enough to prevent APP b-cleavage. Lipid
rafts in the membrane also have increased BACE1 activity and
decreased a-secretase activity (Ehehalt et al., 2003). It is likely
that b-cleavage in lipid rafts contributes to Ab generation; how-
ever, thebulk ofAbgeneration, approximately 70%, is dependent
on endocytic recycling (Cirrito et al., 2008).
Histological evidence suggests that dysfunction of endocytic
recycling is one of the earliest pathological changes in AD. In
postmortem studies of AD patients, early endosomes were
enlarged up to 32-fold the volume of normal endosomes (Cata-
ldo et al., 1997). In theory, the enlarged endosomes give APP
more time to interact with b- and g-secretases and thus generate
more Ab. Remarkably, endosomal enlargement begins prior to
the appearance of clinical disease in APOE ε4 carriers, and this
finding was reproduced in induced pluripotent stem cells derived
from AD patient fibroblasts (Cataldo et al., 2000; Israel et al.,
2012). Partly because of these findings, recent AD research
has focused on changes in endosome recycling associated
with the members of the LDL receptor family.
Several members of the lipoprotein receptor family affect APP
endocytosis. For example, LRP1 has an endocytosis rate that is
much faster than APP. As a result, when the LRP1 extracellular
domain interacts with APP, APP endocytosis is accelerated,
leading to increased processing to Ab (Cam et al., 2005). Over-
expression of a functional LRP1 minireceptor led to increased
soluble Ab levels in the PDAPP mouse model (Zerbinatti et al.,
2004, 2006). However, LRP1 also plays a role in promoting
neuronal Ab clearance and neuronally restricted disruption of
Lrp1 in APP/PS1 model mice accelerated Ab accumulation
(Kanekiyo et al., 2013). Additionally, the scaffolding protein
RanBP9 increases APP localization to lipid rafts and enhances
the association of LRP1, APP, and BACE1, to increase Ab gen-
eration (Lakshmana et al., 2009). RanBP9 is increased in AD
brains and in APPmice, suggesting that it may have a role in dis-
ease pathogenesis (Lakshmana et al., 2010; Woo et al., 2012). A
newly identified member of the LDLR family, low-density-lipo-
protein receptor class A domain containing 3 (LRAD3), also binds
to APP and promotes amyloidogenic processing (Ranganathan
et al., 2011). In contrast to LRP1 and LRAD3, the related receptor
LRP1B has a slower rate of endocytosis and retains APP at the
cell surface, which leads to decreased Ab generation (Cam
et al., 2004). Similarly, LRP10, another novel LDLR family mem-
ber, binds to APP and promotes its trafficking to the Golgi com-
plex, which also prevents amyloidogenic processing (Brodeur
et al., 2012).
The role of the LDL receptor family member Apoer2 in the en-
docytic processing of APP is less clear. Apoer2 alone, in the
absence of ligand, can cause APP localization to lipid rafts,
Figure 2. APP Processing and Endocytosis
In the proamyloidogenic pathway, APP is cleaved
sequentially by BACE1 to sAPPb and C99 (Cai
et al., 2001), and then sAPPb is cleaved by
g-secretase to Ab and AICD (St George-Hyslop
and Fraser, 2012). In the nonamyloidogenic
pathway, a-secretase cleaves APP through the
Ab region to generate C83 and sAPPa, which is
cleaved to P3 and AICD by g-secretase (Vingt-
deux and Marambaud, 2012). b-cleavage is
favored in the endosome and in lipid rafts,
while a-cleavage is favored at the cell surface
outside of lipid rafts (Ehehalt et al., 2003).
Several members of the low-density lipoprotein
receptor family affect APP localization. LRP1 in-
creases APP trafficking to the endosome (Cam
et al., 2005), while LRP1B decreases trafficking
(Cam et al., 2004). Apoer2 can direct APP to
lipid rafts independently or to a-secretase in the
presence of F-spondin (Hoe et al., 2005). SORLA
can prevent a- and b-cleavage and promotes APP
transport to the Golgi (Andersen et al., 2005;
Schmidt et al., 2007). Ab, amyloid beta; AICD,
APP intracellular domain; Apoer2, apolipoprotein
E receptor-2; APP, amyloid precursor protein;
Arc, activity-regulated cytoskeleton-associated
protein; BACE1, beta-site APP cleaving en-
zyme 1; C83, APP C-terminal C83 fragment; C99, APP C-terminal C99 fragment; LRP1, low-density lipoprotein receptor-related protein 1; LRP1B, low-density
lipoprotein receptor-related protein 1B; sAPPa, soluble APP a; sAPPb, soluble APP b; SORLA, sortilin-related receptor.
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cytosis (Fuentealba et al., 2007). In the presence of F-spondin,
which interacts with Apoer2 and APP, Apoer2’s slower endocy-
tosis rate inhibits APP endocytosis, maintaining APP at the sur-
face and reducing Ab generation (Hoe et al., 2005). However,
ApoE binding to Apoer2 causes endocytosis of APP, Apoer2,
and BACE1 (He et al., 2007). Together, these data suggest that
the effect of Apoer2 on APP endocytosis depends on the ligands
present. Intriguingly, VLDLR and APP can increase each other’s
surface expression through mutual interactions with Fe65
(Dumanis et al., 2012).
In addition to the LDL receptor gene family of ApoE receptors,
members of the structurally related Vps10p domain-containing
receptor family are also involved in APP trafficking. Sorting pro-
tein-related receptor with A-type repeats (SorLA, alternatively
SORL1 or LR11) is a neuronal Vps10p-containing receptor that
interacts with APP and generally reduces its cleavage by either
a- or b-secretases (Schmidt et al., 2007). Human studies have
shown that SorLA is decreased in late-onset AD, and certain ge-
netic variants of SORL1 are associated with AD, indicating a
possible pathogenic role for SorLA (Dodson et al., 2006;
Rogaeva et al., 2007; Scherzer et al., 2004). Recent data support
a novel inhibitory mechanism for SorLA, where it binds to APP
monomers and prevents them from forming dimers, which are
the preferred ligands for both a- and b-secretases (Schmidt
et al., 2012). Overexpression of SorLA causes the redistribution
of APP to theGolgi complex, where all secretases are less active,
leading to a decrease in Ab levels (Andersen et al., 2005).
Recently, another member of the Vps10p family, sortilin, was
identified as being involvedwith APP endocytosis in vitro. Sortilin
promotes the endocytosis of APP and the generation of sAPPa
(Gustafsen et al., 2013). However, an in vivo study in sortilin
knockout mice did not reveal a change in sAPPa or sAPPb levels
(Carlo et al., 2013) (Figure 2).Alterations in endocytosis of APP clearly play a role in the
pathology of AD, based on evidence from patient tissue and
mouse models of disease. However, it is still not entirely clear
what role ApoE isoforms play physiologically in APP endocytosis
and subsequent Ab generation. In one study, the ApoE4 isoform
caused increased endocytosis of APP, Apoer2, and BACE1 in
neuroblastoma cells (He et al., 2007). Another study showed
that ApoE4 delayed recycling of endosomes in hepatocytes
(Heeren et al., 2004) and neuronal cells (Rellin et al., 2008). How-
ever, in vivo studies using microdialysis of the interstitial fluid
(ISF) in ApoE transgenic mice showed that ApoE isoform has
no effect on Ab synthesis, only its clearance (Castellano et al.,
2011).
Synaptic Activity Increases Ab Generation
The physiological role of Ab has long been debated. A few
studies have demonstrated that blocking Ab in youngmice leads
to reduced performance on memory tasks, suggesting that at
low levels Ab plays a role in synaptic function (Abramov et al.,
2009; Morley et al., 2010; Puzzo et al., 2008, 2011). Remarkably,
synaptic activity increases levels of extracellular Ab and de-
creases levels of intraneuronal Ab (Cirrito et al., 2005). This is
achieved by two separate mechanisms. First, the activity-
dependent generation of extracellular Ab is dependent on APP
endocytosis and processing by BACE1 and g-secretase (Cirrito
et al., 2008; Kamenetz et al., 2003). This is in part mediated by
Arc, an intermediate early gene that is expressed shortly
following synaptic activity (Soule´ et al., 2008). Arc increases
the association of g-secretase with APP in endosomes (Wu
et al., 2011). Conversely, synaptic activity decreases intraneuro-
nal Ab42 through increased processing by neprilysin, the main
Ab protease (Tampellini et al., 2009). Intriguingly, these results
suggest a physiological role for Ab. In response to synaptic activ-
ity, Ab is increased extracellularly, which dampens LTP atNeuron 83, August 20, 2014 ª2014 Elsevier Inc. 775
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including NMDA receptors, mGluR5, and PrPc (Laure´n et al.,
2009; Li et al., 2011a; Renner et al., 2010). This could indicate
that Ab is involved in homeostatic scaling, a process in which
highly active synapses begin to dampen their responses, and
less active ones become more sensitive (reviewed in Sheng
et al., 2012).
Reelin, Ab, and Tau at the Synapse
Ab oligomers have been shown to inhibit LTP induction (Nomura
et al., 2012; Shankar et al., 2008;Walsh et al., 2002). Ab activates
caspase-3 through a mechanism that is currently unknown but
probably involves mitochondrial dysfunction. Caspase-3 then
activates PP2B (calcineurin), which directly dephosphorylates
NMDAR at the Fyn phosphorylation site (D’Amelio et al., 2011;
Kim et al., 2009; Snyder et al., 2005). Caspase-3 also cleaves
Akt, rendering Akt inactive and unable to phosphorylate and
inhibit GSK3b (Jo et al., 2011). When left uninhibited, GSK3b
blocks LTP induction by an unknown mechanism that may
involve tau (see below). Reelin has the opposite effect from Ab
on GSK3b activity. Dab1 activates PI3K, which activates Akt,
leading to decreased GSK3b activation (Beffert et al., 2002).
Convincingly, Ab inhibition of LTP in hippocampal slices is pre-
vented by coapplication of Reelin in the ACSF (Durakoglugil
et al., 2009). Thus, Reelin signaling through ApoE receptors
intersects with Ab at the level of tyrosine phosphorylation of
NMDA receptors and GSK3b activation to affect LTP induction,
learning, and memory (Figure 1A).
As previously mentioned, the two main Reelin receptors,
Apoer2 and Vldlr, also bind ApoE. Different ApoE isoforms differ-
entially affect Reelin’s ability to signal through the ApoE recep-
tors by interfering with receptor recycling to and from the
synapse. Once Reelin activates its receptors, the receptors are
endocytosed, along with Reelin and ApoE. While ApoE2 and
ApoE3 do not significantly interfere with endosomal recycling,
ApoE4 impairs it. This impaired recycling decreases the available
surface pool of Apoer2 and thus Reelin signaling (Figure 1B). As a
result, hippocampal slices from ApoE4 transgenic mice do not
enhance LTP upon Reelin addition to the perfusate (Chen
et al., 2010). Importantly, because Reelin is unable to efficiently
signal in ApoE4 knockin mice, Reelin is unable to protect against
the Ab-induced synaptic suppression. Consequently, ApoE4
promotes increased susceptibility to Ab damage at the synapse
(Chen et al., 2010).
The importance of Reelin in AD pathology is implicated by
several studies. Reelin levels are reduced in the entorhinal cortex
in postmortem AD brain and hAPP mouse models (Chin et al.,
2007; Herring et al., 2012). Interestingly, another group found
that Reelin levels were elevated in frontal cortex of AD patients,
suggesting potential compensation in that region for elevated Ab
levels (Botella-Lo´pez et al., 2006, 2010). Additionally, cognitively
normal individuals with a high level of plaques and tangles
possess certain SNPs in RELN that may make them more prone
to elevating Reelin levels in response to high Ab load (Kramer
et al., 2011; for review, see Krstic et al., 2013). Finally, Reelin is
not the only ligand that binds to Apoer2 and Vldlr to activate
Dab1 signaling. Clusterin, aka ApoJ, also binds to Apoer2 and
Vldlr and can activate Reelin signaling (Andersen et al., 2003;776 Neuron 83, August 20, 2014 ª2014 Elsevier Inc.Leeb et al., 2014). Clusterin SNPs are associated with AD, and
clusterin levels are elevated in AD (Harold et al., 2009; Lambert
et al., 2009; May et al., 1990), further highlighting the role of
ApoE receptors in AD pathogenesis.
As described earlier, activation of the Reelin pathway culmi-
nates in GSK3b inhibition. In many disease states, including
Alzheimer’s disease, GSK3b is unregulated, leading to its over-
activation (Jope et al., 2007). One proposed mechanism for
GSK3b’s effects on synaptic plasticity is tau hyperphosphoryla-
tion. Aggregated, hyperphosphorylated tau comprises the sec-
ond pathological hallmark of AD, neurofibrillary tangles (NFTs).
In a diseased brain, tau becomes phosphorylated at several
sites by a number of kinases, leading to its detachment from
the microtubule (Go¨tz et al., 2010). Hyperphosphorylated tau
migrates from the axonal compartment to the somatodendritic
compartment, where it destabilizes the synapse (Hoover et al.,
2010; Li et al., 2011b). Tau aggregates to form NFTs, ultimately
resulting in neuronal death. Remarkably, activated GSK3b is
one of the kinases that phosphorylates tau, indicating a potential
mechanism for its inhibition of LTP (Mulot et al., 1994). Indeed,
hippocampal slices from tau knockout mice are resistant to
Ab-induced LTP reduction (Shipton et al., 2011), as well as
learning and memory deficits (Roberson et al., 2007).
The effect of Reelin pathway dysfunction on tau phosphoryla-
tion appears to be strain specific. While some mouse strains
have high levels of tau hyperphosphorylation in the absence of
Dab1, other strains are relatively unaffected. A quantitative trait
locus analysis comparing Dab1-deficient mice with high or low
levels of tau phosphorylation revealed a strong hit on chromo-
some 16 at a locus that includes the genes for APP and SOD,
as well as a suggestive hit at the locus that includes Psen1 (Brich
et al., 2003). The genetic interplay between these key proteins
highlights the integrative effects of the Ab, Reelin, and tau path-
ways in disease pathogenesis.
The process by which dendritic tau causes synaptic dysfunc-
tion is largely unknown. One hypothesis is that tau acts as a car-
rier for Fyn kinase to the dendrites. At the synapse, Fyn kinase
phosphorylates the NR2 subunit of NMDA receptors, which facil-
itates its interaction with PSD-95, and may lead to increased
glutamate excitotoxicity. In the absence of tau, or with a trun-
cated version of tau incapable of entering the dendrite (Dtau),
Fyn remains localized to the soma. As a result, APP23 mice
with no tau or Dtau have fewer memory deficits despite having
similar levels of APP and Ab as those with full-length tau (Ittner
et al., 2010). Fyn’s role in tau pathology is supported by the
fact that overexpression of Fyn leads to greater impairment in
spatial learning in APP mice (Chin et al., 2005). However, the
tau-Fyn hypothesis, reviewed in depth in Ittner and Go¨tz
(2011), is seemingly at odds with the physiological requirement
for Fyn at the synapse and with the proposed mechanism of
Reelin enhancement of LTP (Grant et al., 1992). As described
above, Reelin activates Fyn kinase, but this enhances LTP,
rather than causing excitotoxicity. The answer to this conundrum
may lie in a different compartmentalization of these effectors: for
example, the effect of Ab and tau on extrasynaptic versus synap-
tic NMDA receptors, and the role of NR2B versus NR2A subunits
(Hardingham et al., 2002; Tackenberg et al., 2013; Talantova
et al., 2013; see Parsons and Raymond, 2014 for a review).
Figure 3. Removing Ab from the CNS
Ab can be degraded by IDE in the ISF or taken up intomicroglia for degradation
by neprilysin (Nep) (Jiang et al., 2008; Qiu et al., 1998). Ab can also be cleared
across the BBB to the plasma, where it is degraded by plasma proteases. This
process is affected by Ab binding to ApoE particles. While ApoE3 uses both
Vldlr and LRP1 to cross the BBB, ApoE4 primarily uses Vldlr, which results in
slower efflux (Deane et al., 2008). Lipidated ApoE is more effective at trans-
porting Ab across the BBB than alipidated forms (Jiang et al., 2008). ABCA1 is
a membrane protein that lipidates ApoE particles (Lawn et al., 1999) and
whose expression is upregulated by LXR and RXR (Beaven and Tontonoz,
2006). Finally, when the tight junctions of the BBB are weakened, Ab can leak
back into the ISF (Clifford et al., 2007). Ab, amyloid beta; ABCA1, ATP-binding
cassette transporter; AD, Alzheimer’s disease; ApoE, apopolipoprotein E;
APP, amyloid precursor protein BBB, blood-brain barrier; IDE, insulin-
degrading enzyme; ISF, interstitial fluid; LRP1, low-density lipoprotein re-
ceptor-related protein 1; LXR, liver X receptor; RXR, retinoid X receptor; Vldlr,
very-low-density lipoprotein receptor.
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tions of Ab, tau, and Reelin at the synapse.
ApoE and Ab Clearance
Once Ab is generated by secretase cleavage, it is released to the
ISF where it is cleared by a variety of mechanisms: efflux across
the blood-brain barrier (BBB), uptake by cells for lysosomal
degradation, and cleavage by Ab-specific proteases. Dysfunc-
tional clearance of Ab plays a key role in amyloid accumulation,
since late-onsetADpatientsdonot have increasedAbproduction
but rather insufficient Ab clearance (Mawuenyega et al., 2010).
Further, Ab42 is generally cleared more slowly than Ab40, which
leads to a preferential accumulation of the more toxic species
(Bell et al., 2007). Ab is cleared from the ISF in an ApoE-isoform
dependent manner: ApoE2 allows for the more rapid clearance
of Ab in vivo, while ApoE4 slows clearance. Thus, the presence
of ApoE4 promotes the buildup of Ab in the ISF (Castellano
et al., 2011). The ApoE receptors LRP1, LDLR, and VLDLR all
appear toplay a key role in theclearanceofAb. As theseAb-clear-
ing effects of ApoE were recently reviewed in depth (Kanekiyo
et al., 2014), we will only touch on them briefly here.One method of Ab clearance is efflux across the BBB to the
periphery, where Ab is rapidly degraded in the plasma. ApoE re-
ceptors directly mediate this process, primarily LRP1, which
uses its ligands, a2-macroglobulin, RAP, or ApoE, to promote
Ab efflux (Bell et al., 2007; Hughes et al., 1998; Kanekiyo and
Bu, 2009; Narita et al., 1997). ApoE2 and ApoE3 use both LRP1
and Vldlr to cross the BBB, leading to faster Ab efflux. ApoE4
shifts Ab transport from LRP1 to Vldlr, resulting in a slower rate
of clearance and buildup of Ab in the ISF (Deane et al., 2008).
The LDLR was also recently found to promote Ab efflux across
the BBB (Castellano et al., 2012). While it is clear that lipoprotein
receptors have a large effect on Ab efflux at theBBB, further work
is required to elucidate their exact mechanisms of action.
Normally, transport across the BBB is highly regulated by
transporters such as the lipoprotein receptors; however, if the
BBB is damaged, this regulation is lost. Perhaps unsurprisingly,
the BBB is found to be defective in some, but not all, postmortem
AD samples (Clifford et al., 2007). If the BBB has been damaged,
Ab species may leak back into the CNS and accumulate in neu-
rons, contributing to amyloid pathology (Clifford et al., 2007).
In vitro experiments disagree on the role of ApoE and its isoforms
on BBB maintenance (Hafezi-Moghadam et al., 2007; Nishitsuji
et al., 2011). The importance of ApoE4 in BBB stability in vivo
needs to be clarified, since only some AD patients have a weak-
ened BBB, and the deterioration might be a result of disease
pathology, rather than the cause.
In addition to efflux across the BBB, Ab can be cleared cen-
trally by endocytic trafficking to lysosomes or degradation by
Ab proteases. ApoE3 promotes Ab uptake and degradation by
lysosomes in vitro, while ApoE4 has a weaker effect (Li et al.,
2012). In addition to lysosomal proteases, there are two Ab-spe-
cific proteases. Intracellularly, the degradation of Ab is mediated
by neprilysin. While all ApoE isoforms enhance Ab degradation
by neprilysin, ApoE4 appears to have the weakest effect
in vitro (Jiang et al., 2008). Extracellularly, the degradation of
Ab is mediated by insulin-degrading enzyme (IDE), a protease
that is released by microglia and astrocytes into the extracellular
milieu and whose levels are reduced by ApoE4 (Jiang et al.,
2008; Qiu et al., 1998).
The interaction between ApoE and Ab is affected by the
lipidation state of ApoE. It has been shown in vitro that lipidated
ApoE is more effective at promoting both Ab efflux across the
BBB and Ab degradation by proteases (Jiang et al., 2008). Lipi-
dated ApoE is generated in the brain by ATP binding cassette
transporter A1 (ABCA1), which transfers cholesterol from the
plasma membrane to lipid-poor ApoE (Lawn et al., 1999). Over-
expression of ABCA1 increases ApoE lipidation and reduces
amyloid deposition in a mouse model of AD (Wahrle et al.,
2008); conversely, decreasing ABCA1 expression has the oppo-
site effect (Wahrle et al., 2005). One explanation for this effect is
that ApoE binds Abmore efficiently when lipidated (Tokuda et al.,
2000); however, ApoE shows minimal interaction with Ab in vivo
and may instead affect Ab clearance indirectly (Verghese et al.,
2013) (Figure 3).
Finally, Ab binding to lipidated ApoE particles can also be
enhanced by the acquisition of sulfatides, sulfated derivatives
of galactocerebrosides that are primarily produced by oligoden-
drocytes and form the major components of the myelin sheathNeuron 83, August 20, 2014 ª2014 Elsevier Inc. 777
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the presence of sulfatides promotes Ab clearance through
ApoE-mediated endocytosis. In AD patients, the sulfatide con-
tent in the CNS is reduced, which is mirrored by a reduction of
sulfatides in the CSF (Han et al., 2002; Han et al., 2003). This sul-
fatide loss is specific to AD, as it is not found in other neurode-
generative diseases such as Parkinson’s and dementia with
Lewy bodies (Cheng et al., 2003). Lipoprotein receptors play a
specific role in this process, as reduction of Lrp1 led to sulfatide
loss in a mouse model (Liu et al., 2010).
As described earlier, lipoprotein receptors affect both Ab pro-
duction and clearance. A few key mouse and human studies
strongly suggest that clearance is the process primarily affected
in AD and by ApoE isoforms (Castellano et al., 2011; Mawue-
nyega et al., 2010). However, it is also important to note that
ApoE4 carriers and preclinical AD patients have hyperactivity
in several brain regions and that increased synaptic activity leads
to overproduction of Ab (Cirrito et al., 2005; Filippini et al., 2009;
Quiroz et al., 2010; for review, see Palop and Mucke, 2010).
Whether Ab buildup causes hyperactivity or vice versa in the
early phases of disease is still debated.
Vascular Ab and Lipoprotein Receptors
Cerebral amyloid angiopathy (CAA) is the deposition of amyloid
in brain capillaries, leptomeningal vessels, and arterioles. Most
commonly, CAA is the result of deposition of Ab in the smooth
muscle cell layer, which gradually replaces the smooth muscle
wall and leaves the vessel more susceptible to hemorrhage
(Vinters, 1987). The majority of patients with AD also have
CAA, which can independently trigger intracranial hemorrhage
and progressive dementia (Ellis et al., 1996; Rensink et al.,
2003). Similar to AD, possession of the ApoE4 allele causes
patients to be more susceptible to CAA and hemorrhage, a
finding which is mirrored in mouse models of AD (Fryer et al.,
2005; Greenberg et al., 1995). Interestingly, ApoE2, which is pro-
tective for AD, is associated with an increased risk of hemor-
rhage when CAA is present (Nicoll et al., 1996).
Ab drains out of the CNS through ISF drainage pathways in the
smooth muscle cell layer of arterioles, leptomeningal arteries,
and capillaries, which is primarily where Ab builds up in CAA.
Lrp1 is required for clearance of Ab through smoothmuscle cells,
since smooth muscle cell-specific knockout of Lrp1 leads to the
buildup of both parenchymal amyloid plaques and CAA in a
mouse model of AD (Kanekiyo et al., 2012). Smooth muscle
cell levels of Lrp1 are reduced in AD (Bell et al., 2009). It is not
yet clear if Lrp1 is the only lipoprotein receptor involved in
CAA, or if it is the mechanism by which ApoE4 increases CAA
risk. For an in-depth review of neurovascular dysfunction in
AD, see Zlokovic (2011).
ApoE Fragmentation
Full-length ApoE may not be the only ApoE form that is involved
in AD pathology. In postmortem AD brains, there is an accumu-
lation of C-terminal-truncated ApoE (Huang et al., 2001). While
this could simply be the result of increased degradation of
ApoE, it has been shown that the addition of ApoE fragments
to neuronal cultures leads to the accumulation of NFTs (Brecht
et al., 2004). Cell stress in neurons in vitro results in ApoE frag-778 Neuron 83, August 20, 2014 ª2014 Elsevier Inc.mentation and the generation of toxic C-terminal-truncated frag-
ments, which can escape the secretory pathway and cause NFT
formation (Brecht et al., 2004). ApoE4 is particularly susceptible
to proteolysis due to a domain interaction between Arg-61 and
Glu-255, which is facilitated by the Arg-112 specific to apoE4
(Dong and Weisgraber, 1996; Dong et al., 1994), and expression
of truncated ApoE4 in transgenic mice leads to AD-like neurode-
generation and death (Harris et al., 2003). These studies, re-
viewed in Mahley and Huang (2012), indicate a role for ApoE
fragments as toxic particles that may cause t aggregation
(Brecht et al., 2004), rather than just as markers of ApoE degra-
dation. It is important to point out that ApoE expression is nor-
mally absent in neurons but occurs under stress conditions (Xu
et al., 2008), and the fragmentation hypothesis requires ApoE
to be present in the neuron at the time of injury in order for pro-
teolysis to occur.
The Common Thread: ApoE4 and Endocytic Recycling
The seemingly disparate effects of ApoE4—altered APP pro-
cessing, reduced Ab clearance, and impaired synaptic plas-
ticity—share a common mechanism: alterations in endocyctic
recycling. To understand this finding, one must remember that
the role of lipoprotein receptors and apolipoproteins in the pe-
riphery is to transport cholesterol- and triglyceride-rich lipopro-
teins. In hepatocytes, ApoE-containing particles are taken up
primarily through LRP1 and LDLR (Beisiegel et al., 1989; Rohl-
mann et al., 1998). While cholesterol and ApoB are transported
to the lysosome, ApoE recycles back to the surface (Rensen
et al., 2000). However, ApoE4 recycles poorly in comparison to
the other isoforms, leading to its intracellular accumulation (Hee-
ren et al., 2004). The reason for this may be that at the lower pH
that prevails in endosomes, ApoE4 ismore likely to form amolten
globule (Morrow et al., 2002). The altered structure of ApoE4 at
low pH may make it more prone to aggregation, leading to dis-
rupted retroendocytosis.
As described in the previous sections, the disruption of endo-
cytic recycling by ApoE4 plays a key role in AD. First, ApoE4 has
been reported to promote colocalization of APP and BACE1 in
early endosomes, which may lead to increased processing of
APP (Rhinn et al., 2013). Second, ApoE4 promotes intraneuronal
buildup of Ab by affecting its trafficking (Zhao et al., 2014).
Finally, ApoE4 causes reduced surface expression of Reelin re-
ceptors, blocking Reelin’s ability to protect the synapse against
Ab toxicity (Chen et al., 2010). While the relative contributions of
these three mechanisms to AD pathogenesis remain to be deter-
mined, these data nevertheless clearly show that trafficking pre-
sents an appealing target for AD prevention. Furthermore, a
recent genomic study showed that gene expression changes
in endocytic trafficking molecules were common to both
ApoE4 carriers and LOAD patients (Rhinn et al., 2013). One of
the identified trafficking proteins was SV2A, a synaptic vesicle
protein. Treatment of human fibroblasts with Levetiracetam, an
inhibitor of SV2A, reversed both the endosomal trafficking
dysfunction and upregulated APP processing caused by
ApoE4 but had no effect in the presence of ApoE3 (Rhinn
et al., 2013). Levetiracetam also reversed behavioral and electro-
physiological deficits in the hAPP mouse model of AD, and it
reversed the abnormal hippocampal hyperactivity found in mild
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chez et al., 2012). Levetiracetam is currently used clinically for
the treatment of epilepsy, where it has several significant side ef-
fects, includingmood disorders and excessive sleepiness (Boot-
sma et al., 2007). It is currently unknown if these are on- or off-
target effects, and while inhibiting SV2A with Levetiracetam
may not be the ideal therapeutic strategy, taken together with
other findings, these results strongly indicate that restoring en-
docytic recycling is an attractive strategy for preventing AD.
Insights and Developments in Diagnostics
The abundance of molecular data on the role of ApoE receptors
and Ab in AD is now setting the stage for increasingly rational and
sophisticated diagnostic and therapeutic approaches. In our
clinics today, the prediction, diagnosis, and monitoring of Alz-
heimer’s disease remains inexact. Drug testing and develop-
ment occurs either in patients with advanced disease, for
whom interventions may be too late, or in a cohort of as yet
unaffected individuals, which necessarily thenmust be very large
to achieve statistical significance. Similarly, drug efficacy is
primarily determined by cognition scores, which may take
months or years to change significantly compared to the placebo
control group. It is thus important to develop new ways to
monitor disease, and the clinical evaluation of AD is rapidly being
transformed by the development of new imaging techniques and
biomarkers.
Historically, the diagnosis of AD could only be confirmed after
death via detection of amyloid plaques and neurofibrillary tan-
gles. Through recent advances in noninvasive imaging technol-
ogy, amyloid deposition can now be observed in living patients
using positron-electron tomography (PET). Patients are injected
with Pittsburgh B (PIB) or similar compounds, which are PET
tracers that bind to amyloid in the brain (Klunk et al., 2004).
Studies of PIB imaging have shown that the PIB signal roughly
follows what is already known about amyloid deposition from
postmortem tissue. In cognitively normal individuals, no PIB
signal is present until around 50 years of age, at which point it
starts to appear in a percentage of the population. Once individ-
uals begin to be PIB positive, the amount of signal increases over
time (Morris et al., 2009). As the PIB signal crosses a vague
threshold, cognitive decline starts to occur, with greater PIB
signal predicting greater cognitive loss. Since PIB signal closely
shadows amyloid deposition, one can examine risk factors,
modifiers, and treatments for AD in living patients. For example,
ApoE4 carriers have higher PIB signals at younger ages, while
ApoE2 carriers have lower signals (Reiman et al., 2009). The
PIB signal also increases at a faster rate in ApoE4 carriers
(Grimmer et al., 2010).
While PIB PET reveals the static deposition of amyloid, FDG-
PET and fMRI are able to detect functional loss in the affected
areas of brain. FDG-PET measures glucose metabolism in the
brain, while fMRI can be used to look at blood flow, oxygen con-
sumption, and network connectivity. These tools, reviewed in
Perrin et al. (2009), have shown that changes in connectivity
and brain function occur long before plaque deposition and
cognitive decline in ApoE4 carriers. Cognitively normal ApoE4
carriers already have decreased regional volume byMRI in those
brain areas that are the first to be affected in AD, as well asdecreased glucose metabolism by FDG-PET (Chen et al.,
2012). Similarly, young, PIB-negative, ApoE4 carriers already
have some fMRI connectivity deficits that are similar to those
found in AD patients (Sheline et al., 2010). These functional alter-
ations may begin very early in development, since ApoE4-car-
rying infants as young as 2 months of age exhibited reduced
white matter myelin water fraction (MWF) and gray matter vol-
ume (GMV) in several areas affected in AD (Dean et al., 2014).
Additionally, ApoE4 carriers show greater hippocampal activa-
tion during memory encoding tasks and greater activation of
the ‘‘default mode’’ network at rest (Filippini et al., 2009). Since
neuronal activity leads to increased levels of Ab, increased hip-
pocampal activity may be both, driver and first indicator of amy-
loid accumulation in these patients.
The availability of these new imaging tools has led to important
prospective studies in a large familial AD cohort in Colombia. In-
dividuals in this cohort harbor the E280A mutation of PSEN1,
which shifts APP processing toward generation of longer Ab spe-
cies, particularly Ab42. These individuals follow a temporally
fixed path of disease development (Van Vickle et al., 2008). Dis-
ease onset occurs within a narrow window around 45 years of
age, presenting initially with memory loss and then progressing
to include personality changes, loss of language, and finally
gait abnormalities (Acosta-Baena et al., 2011; Lopera et al.,
1997). Since disease progression is so well characterized in
the Colombian cohort, we can study neurological changes that
occur before the onset of clinical disease. For example, 15 years
prior to disease onset, carriers of the PS1 mutation have
increased hippocampal activation despite similar performance
during memory tasks relative to healthy controls (Quiroz et al.,
2010). The Colombian cohort has already been used to update
AD diagnostic criteria in the clinic. Studies in predementia
E280A carriers identified new cognition tests that could indicate
preclinical dementia, including the Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) memory test, the
naming of famous faces, and semantic variation (Arango-La-
sprilla et al., 2007; Cuetos et al., 2007; Tirado et al., 2008). This
year, clinical trials using anti-amyloid therapeutics will begin in
predementia individuals of the Colombian cohort.
The distinction between ‘‘early-onset’’ AD, found in the
Colombian cohort, and ‘‘late-onset’’ AD, found in the majority
of patients, has a well-understood mechanistic basis. Both dis-
eases involve elevated levels of Ab, which through mechanisms
that are not yet entirely clear triggers tau pathology, cognitive
impairment, and ultimately results in neurodegeneration. How-
ever, both forms of the same disease, i.e., AD, differ mechanis-
tically in that familial AD involves APP mutations that increase
Ab production, whereas ApoE4 impairs clearance of Ab. More-
over, ApoE4 appears to alter brain function early in life (Dean
et al., 2014), whichmay leave certain brain regionsmore suscep-
tible to Ab toxicity (Figure 4).
Alzheimer’s disease is a complex disorder whose underlying
molecular and network dysfunctions continue to emerge. It is
clear that ApoE4 and lipoprotein receptors have pivotal roles in
AD pathogenesis by altering cellular trafficking and Ab clearance
on one hand, as well as affecting synaptic plasticity on the other.
With somany interacting proteins and higher-order network sys-
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Figure 4. ApoE4 and AD Progression
ApoE4 carriers have alterations in brain structure
and function starting early in life, most notably in
AD-related areas. As early as infancy, MRI reveals
that there is reduced gray matter volume in pos-
terior/middle cingulate, lateral temporal, and
medial occipitotemporal regions in ApoE4 carriers,
a trend that continues throughout life (Dean et al.,
2014). These findings aremirrored inmiddle age by
reduced glucose metabolism in the same areas in
ApoE4 carriers, prior to the onset of cognitive
dysfunction (Protas et al., 2013). With age, ApoE4
carriers have earlier deposition of Ab plaques
compared to ApoE3 carriers, which is then fol-
lowed by the development tau tangles and frank
atrophy. The altered baseline brain function and
accelerated Ab deposition combine to cause
ApoE4 carriers to have both an earlier age of dis-
ease onset and a more rapid decline in cognitive
function (Caselli et al., 2009). Ab, amyloid beta; AD,
Alzheimer’s disease; ApoE, apolipoprotein E.
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Reviewan interdisciplinary approach to reduce this unwieldy complexity
to its root causes. We are at a thrilling time in Alzheimer’s
research as new molecular insights into disease mechanisms
reveal novel neurobiological principles and promising therapeu-
tic approaches to feed the desperately needed drug pipeline.
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